Aurobindo Pharma announced that Eugia Pharma Specialities, its wholly owned subsidiary, has received final FDA approval to manufacture and market Azacitidine for Injection, 100 mg Single-Dose Vial.
Azacitidine for Injection, 100 mg Single-Dose Vial is the bioequivalent and therapeutically equivalent to Bristol-Myers Squibb Company’s Reference Listed Drug (RLD), Vidaza for Injection, 100 mg Single-Dose Vial. The product is set to be released this month.